[195 Pages Report] The Tylosin market size is expected to reach USD billion by the end of 2029, and it is growing at a CAGR of 4.2% during the forecast period (2022-2029).
Tylosin is an antibiotic of the macrolide class developed for veterinary use. Tylosin is licensed for use as a broad-spectrum antibiotic for injectable or oral use in the treatment of infections such as respiratory tract and skin infections in livestock. It may also be used as a growth promoter in food animals. As per DataM Intelligence, the research report provides detailed insights on the market size, trends, share, growth, demand, and competitive analysis in the major regions such as North America (United States, Canada), European Countries (Germany, Italy, UK, Spain, France, Russia), Latin America (Mexico, Argentina), Asia Pacific (China, India, Japan, South Korea), Middle East and Africa (Saudi Arabia, UAE, Qatar, and South Africa).
Metrics |
Details |
Market CAGR |
4.2% |
Segments Covered |
By Drug Type, By Application, By Route of Administration, and By Region |
Report Insights Covered |
Competitive Landscape Analysis, Company Profile Analysis, Market Size, Share, Growth, Demand, Recent Developments, Mergers and acquisitions, New Product Launches, Growth Strategies, Revenue Analysis, and Other key insights. |
Fastest Growing Region |
Asia Pacific |
Largest Market Share |
North America |
To know more insights into the Market, Get Our Sample Brochure
The global tylosin market growth is driven by the rising demand for tylosin in the livestock industry. Tylosin is used for the treatment and control of swine dysentery associated with Brachyspira Hyodysenteriae and for the control of porcine proliferate enteropathies in pigs. Moreover, Tylosin is highly effective in tylosin-responsive diarrhea in dogs, which is a canine chronic, recurrent diarrhea that responds repeatedly to tylosin treatment.
Increasing demand for tylosin in the livestock industry is expected to propel growth
The global tylosin market is expected to witness significant growth over the forecast period, owing to rising demand for tylosin in the livestock industry. For instance, according to a study by Ministry for Primary Industries, New Zealand 2016, tylosin accounted for over 83% of macrolide and lincosamide sales between 2011 and 2014, and the trend is expected to continue over the forecast period.
Antimicrobial medications are generally used in the livestock industry for the treatment of various infections in the livestock, prevention of disease, and improving the growth rate of the animal's efficiency. Moreover, antimicrobial medications are effective in animals for improving growth rate and increasing weight more efficiently, which in turn results in increased profits for the meat producers.
Rising income levels and disposable income in emerging economies increase demand
Rising income levels and disposable income in emerging economies have increased in demand for healthy protein sources for consumption as the daily protein need of the body is not met through conventional food sources. According to NCBI, 2015, in Asia, the daily animal protein intake increased from 7 grams per capita per day to 25 grams per capita per day between 1960, and 2013. Countries such as Brazil, Russia, India, China, and South Africa (BRICS) have started implementing intensive livestock production systems to meet this demand (which necessitates the use of antimicrobials). These factors are expected to support the growth of the global Tylosin market over the forecast period.
The potential side effects associated with its use will hamper its market growth
The most common side effects of tylosin use include pain and inflammation at the injection site and mild gastrointestinal upset, such as decreased appetite and diarrhea. This short-acting medication should stop working within 24 hours, although its effects can be longer in pets with liver or kidney disease.
The effects of COVID-19 on livestock medications are still largely unquantified and yet to be fully felt. Movement restrictions and illness are resulting in tylosin shortages and reduced supply of raw materials or other API to its production. Disruption of supply routes has further delayed its supply. In China, the world’s biggest tylosin exporter restrictions have reduced its production in the factories by half, which could affect global trade flows. Thus, the pandemic has decreased sales which hampers the global tylosin market in the forecast period.
The tylosin Tartrate segment is expected to grow at the fastest CAGR during the forecast period (2022-2029)
Tylosin tartrate is a particular type of antibiotic that is commonly used in a variety of animals, including dogs, cats, cattle, horses, and more. This antibiotic serves a wide range of different purposes, but like other antibiotics, it is designed specifically to target and kill certain types of bacteria. Without treating these bacteria, your pet may run the risk of developing an infection. In terms of its effects on animals. In dogs, tylosin tartrate is most commonly used to treat both gastric infections and colitis in particular. Colitis, which is characterized by irritable bowels and a lack of proper consistency in bowel movements, as well as excessive flatulence and general stomach upset, is caused by an influx of harmful bacteria in the gut and digestive tract. Regular treatments of tylosin tartrate have been shown to help eliminate this bacteria, particularly in smaller animals.
The demand for livestock animals for consumption is on the rise worldwide and is expected to maintain positive growth in demand over the forecast period. Subsequently, the demand for infection-free and healthy livestock used primarily for consumption is increasing. However, the prevalence of various microbial infections is high in both humans and animals. For instance, according to the Centers for Disease Control and Prevention (CDC), 2017, zoonotic diseases are common in the U.S. and worldwide and over 6 out of every 10 known infectious diseases in humans are spread from animals. Hence, antibiotics are an important medication for livestock that aids in providing healthy food products for consumption in humans. This factor is driving the growth of the segment in the forecast period.
The livestock are expected to dominate the tylosin market during the forecast period
The major factors responsible for the growth of this segment include the efficiency of tylosin in various diseases or conditions, such as chronic respiratory disease (CRD) associated with Mycoplasma gallisepticum and Mycoplasma synoviae and other infections.
According to National Center for Biotechnology Information (NCBI), 2015, around 80% of antibiotics sold in the U.S. are for livestock and almost 70% of these are medically important. Moreover, according to NCBI, the antimicrobial consumption in livestock is expected to increase by 67% by 2030, and nearly double. These factors are expected to boost the global Tylosin market growth over the forecast period.
Moreover, antibiotics such as tylosin are used in various animal species for the prevention of mycoplasmosis. For instance, animals such as chickens, turkeys, pigs, and calves require oral Tylosin to be administered in the required dosage to prevent mycoplasmosis and to grow healthy livestock. Furthermore, livestock is a major source of income in several emerging economies such as Brazil, which is a major factor expected to contribute to the market growth in the region over the forecast period.
The North American region holds the largest market share global tylosin market
North American region is dominating the global tylosin market and accounted for the largest market share in 2019, owing to a wide range of definitive measures adopted by government animal welfare organizations that are consistently working for overall improvement in animal health.
Apart from the high prevalence of GI disorders, the changing lifestyle, unhealthy eating habits, and high disposable income are contributing to the high growth rates. On the other hand, Asia-Pacific is expected to exhibit the fastest growth rate over the forecast period. Furthermore, technological advancements, a rising incidence of zoonotic diseases, and an increasing number of pet owners are expected to boost the market in this country. Collaborative efforts were undertaken by major companies to enhance their R&D capabilities and ensure high-quality standards are also anticipated to impel demand across this region. Also, the steady importance given to agricultural contribution to these countries makes the owner more responsible for better care of farm animals. The healthcare expenditure compared to other countries, also fuels the market growth in North America. Thus, it should hold a major share of the market, over the forecast period.
The tylosin market is moderately competitive with the presence of local and global companies. Some of the key players which are contributing to the growth of the market include Zoetis, Tairua Pharmaceuticals, Lukang Pharmaceutical, Henan Hualun, Qilu Pharmaceutical (Inner Mongolia) Co., Ltd, Huvepharma, AdvaCare Pharma, Elanco Animal Health, Apeloa Kagyu, and Top Pharm Chemical Group among others. The major players are adopting several growth strategies such as product launches, acquisitions, and collaborations, which are contributing to the growth of the tylosin market globally.
Elanco Animal Health
Overview: Elanco Animal Health Incorporated operates as an animal health care company. The Company develops, manufactures, and markets products for companion and food animals. Elanco Animal Health serves clients worldwide. Elanco Animal Health is located in BASINGSTOKE, United Kingdom, and is part of the Pharmaceutical Manufacturing Industry. Elanco Animal Health has 49 employees at this location and generates $8.66 million in sales (USD).
Product Portfolio: The Company’s portfolio comprised of Farm Animal Products & Services, Pet Animal Products & Services, and Care4Pigs.
What is the Growth Rate of the Tylosin Market?
The Tylosin market is growing at a CAGR of 4.2% during the forecast period (2022-2029).
What Companies Are Included in the Tylosin Market?
The tylosin market is moderately competitive with the presence of local and global companies. Some of the key players which are contributing to the growth of the market include Zoetis, Tairui Pharmaceuticals, Lukang Pharmaceutical, Henan Hualun, Qilu Pharmaceutical (Inner Mongolia) Co., Ltd, Huvepharma, AdvaCare Pharma, Elanco Animal Health, Apeloa Kangyu, and Top Pharm Chemical Group among others.
Colorectal Cancer Drugs Market